Trade Vertex Pharmaceuticals Incorporated - VRTX shares price

1m
5m
15m
30m
1H
4H
1D
1W
Open on web platform

Market info

Min traded quantity:
1
Full name:
Vertex Pharmaceuticals Incorporated
Currency:
USD
Margin:
5%
Stock exchange:
United States of America
Long position overnight fee
-0.0203%
Short position overnight fee
-0.0102%

Trading hours (UTC)

Mon - Fri:
13:30 - 20:00

VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
White Paper Declaration

You might be interested in

A world first

Our advanced web platform is the world’s first regulated tokenised assets exchange.

Crypto as collateral

Trade the global financial markets using Bitcoin or Ethereum.

Security as priority

Authorised by the High Technology Park of Belarus, the European blockchain regulator, the safety of your holdings is guaranteed.

Technical indicators

Keep an eye on your positions with over 75 advanced charts, price analysis and price alerts.

Control your capital

Use stop-loss and take-profit orders to keep what you earn.

Use the world’s first regulated tokenised assets exchange to build a diverse investment portfolio with your crypto holdings. Make your deposits in Bitcoin or Ethereum to trade global financial instruments with competitive leverage and tight spreads. Currency.com keeps your holdings secure and accessible at a glance.

VISA MASTERCARD Yandex Money WIRE Faster payments SEPA PCI BTC ETH